Bukwang Acquires Acer Stake In Pattern Of Venture Investments
This article was originally published in PharmAsia News
Bukwang Pharm has purchased a minority stake in U.S. bioventure Acer Therapeutics, which is seeking to list its shares on Nasdaq early next year. The investment is the sixth the South Korean firm has made together with TVM Life Science Capital to gain investment returns and beef up R&D.
You may also be interested in...
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.